P-635 The impact of force-degraded variants of recombinant human follicle stimulating hormone alfa (r-hFSH alfa) on in-vitro and in-vivo biological activity

Abstract

Abstract Study question Can an in-vitro bioassay assess the potency of r-hFSH-alfa force-degraded variants with similar ability to the in-vivo rat bioassay described in EU Pharmacopoeia (EU-Pharm 2285)? Summary answer The in-vitro bioassay showed similar ability to the in-vivo bioassay for estimating the impact of r-hFSH-alfa variants, resulting from process-related modifications, on biological activity. What is known already The active ingredient of Gonal f® (Merck KGaA), follitropin-alfa (INN, r-hFSH-alfa), mimics the action of endogenous FSH by binding to, and subsequently activating, the hFSH-receptor (FSH-R), regulating cellular metabolism and oocyte survival/maturation. Structural modifications in r-hFSH-alfa glycosylation, oxidation, or other biochemical changes, may occur during the r-hFSH-alfa manufacturing process and may impact its efficacy/safety. The rat in-vivo bioassay (EU Pharmacopeia) is routinely used to assess r-hFSH-alfa potency by measuring ovarian weight increase. We evaluated whether an in-vitro bioassay has the same ability as the rat in-vivo bioassay to detect changes in biological activity caused by r-hFSH-alfa structural modifications. Study design, size, duration Three r-hFSH-alfa (Gonal f®) batches were stressed under eight chemical/physical/enzymatic treatments. The resulting degraded samples were compared with untreated samples using in-vivo and in-vitro bioassays. Participants/materials, setting, methods Force-degraded r-hFSH-alfa variants were produced by chromatographic separation (acidic/basic enrichment), chemical/physical stress (acidic/basic pH incubation, thermal/oxidative stress) and enzymatic treatments (de-galactosylation and de-sialylation). r-hFSH-alfa potency was measured via a rat in-vivo bioassay (European Pharmacopoeia 2285), assessing ovarian weight increase, and an in-vitro bioassay (cell line expressing the transmembrane hFSH-R), assessing cell-specific metabolic cascade. Force-degraded and untreated samples were compared via analysis of variance. Main results and the role of chance All force-degraded samples were characterized by the chemical/physical analyses panel for quality control. r-hFSH-alfa forced degradation modified the critical quality attributes of the samples; namely, increased the presence of r-hFSH-alfa oxidized forms and/or free subunits up to 50% above product specification, and modified the sialic acid level across variants, generating significantly more hypo-sialylated forms when compared with the untreated control samples. The increase in r-hFSH-alfa free subunits significantly reduced r-h-FSH-alfa biological activity compared with untreated samples, in both the in-vivo and in-vitro assays (p < 0.001 for both). The increase in r-hFSH-alfa oxidized forms significantly reduced r-hFSH-alfa biological activity in-vitro (p <0.001) and, to a lesser extent, in-vivo (p <0.006). A gradual decrease in r-hFSH-alfa sialylation decreased r-hFSH-alfa biological activity in-vivo, indicating a second-order polynomial correlation, and increased r-hFSH-alfa biological activity in-vitro, indicating a negative linear correlation (slope significance p<0.001, R2=0.996). De-sialylation reduces r-hFSH-alfa steric hindrance during the interaction of r-hFSH-alfa and the FSH-R, increasing both r-hFSH-alfa–FSH-R affinity and r-hFSH-alfa biological activity in-vitro, while increasing the rate of r-hFSH-alfa metabolism, resulting in decreased r-hFSH-alfa biological activity in-vivo. Both assays showed a similar ability to identify differences in critical quality attribute levels (sialylation, oxidation, free-subunits), with the intent to identify out-of-specification batches. Limitations, reasons for caution r-hFSH-alfa forced degradation produced more than one structural/chemical modification in most variants (except for de-sialylation); therefore, the effect of discrete modifications could not be studied. Additional studies are needed to show that in-vitro methods can ultimately replace in-vivo bioassays to identify differences in critical quality attribute levels during r-hFSH-alfa manufacturing. Wider implications of the findings Chemical and/or structural modifications of r-hFSH-alfa strongly impact r-hFSH-alfa biological activity and related potency. The development of an in-vitro bioassay for the accurate measurement of r-hFSH-alfa potency may serve to replace the in-vivo bioassay, according to EMA indications (CPMP/SWP728/95). Trial registration number not applicable